TY - JOUR
T1 - Pathologic diagnosis of acute lymphocytic leukemia
AU - Lai, R.
AU - Hirsch-Ginsberg, C. F.
AU - Bueso-Ramos, C.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2000
Y1 - 2000
N2 - With present knowledge, the optimal management of individual patients with acute leukemia requires that every case be studied by morphology, cytochemistry, cytogenetic, immunologic and molecular techniques. An algorithm for diagnostic evaluation and classification of ALL is provided in Fig. 11. Other techniques, such as DNA or cDNA microarray, are at present important research tools but have not yet had a major effect on patient care. More detailed studies of individual patients need to be conducted at specialized cancer centers, where preservation of cells, DNA, RNA, or protein is possible. Such investigations will yield important information on the clinical importance of the expression of various markers, the prevalence and relevance of bilineage and biphenotypic leukemias, and above all will reveal the mechanisms of leukemogenesis and of disease evolution. Such insights wile further aid clinicians in treating ALL and in preventing refractory disease.
AB - With present knowledge, the optimal management of individual patients with acute leukemia requires that every case be studied by morphology, cytochemistry, cytogenetic, immunologic and molecular techniques. An algorithm for diagnostic evaluation and classification of ALL is provided in Fig. 11. Other techniques, such as DNA or cDNA microarray, are at present important research tools but have not yet had a major effect on patient care. More detailed studies of individual patients need to be conducted at specialized cancer centers, where preservation of cells, DNA, RNA, or protein is possible. Such investigations will yield important information on the clinical importance of the expression of various markers, the prevalence and relevance of bilineage and biphenotypic leukemias, and above all will reveal the mechanisms of leukemogenesis and of disease evolution. Such insights wile further aid clinicians in treating ALL and in preventing refractory disease.
UR - http://www.scopus.com/inward/record.url?scp=0033636346&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033636346&partnerID=8YFLogxK
U2 - 10.1016/S0889-8588(05)70183-0
DO - 10.1016/S0889-8588(05)70183-0
M3 - Article
C2 - 11147220
AN - SCOPUS:0033636346
SN - 0889-8588
VL - 14
SP - 1209
EP - 1235
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 6
ER -